<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584610</url>
  </required_header>
  <id_info>
    <org_study_id>07-211</org_study_id>
    <nct_id>NCT00584610</nct_id>
  </id_info>
  <brief_title>The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots</brief_title>
  <official_title>The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to assess the effect of a levonorgesterel-releasing&#xD;
      intrauterine device (LNG IUD, Mirena速) versus a copper IUD (Paraguard速) on coagulation&#xD;
      parameters known to be associated with risk of thrombosis (blood clots). Both the LNG IUD and&#xD;
      the copper IUD are FDA approved devices for contraception.&#xD;
&#xD;
      Women enrolled in this study will be randomized to receive either the LNG IUD or the copper&#xD;
      IUD. They will complete a one month bleeding diary prior to insertion of the IUD and again&#xD;
      for one month while the IUD is in place. They will undergo phlebotomy (blood draw) at&#xD;
      baseline (prior to insertion of the IUD), two and four months. Stored samples will be used to&#xD;
      measure D-dimer, C-reactive protein (CRP), antithrombin (AT), factor VIIIc, activated partial&#xD;
      thromboplastin time (aPTT) and activated partial thromboplastin time plus activated protein C&#xD;
      (aPTT + APC). Both groups will undergo a GYN exam with screening for bacterial vaginosis and&#xD;
      gonorrhea/chlamydia cultures prior to insertion of the IUD. A brief survey to assess the&#xD;
      women's experience with the IUD, including symptomatology and satisfaction with the device,&#xD;
      will be conducted at the four months after insertion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of this study will be change in coagulation parameters, with sample size calculations powered to detect a 35% change in D-dimer within groups and a 50% difference between groups.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with IUD device</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in bleeding patterns between groups</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Blood Coagulation Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel-containing intrauterine device insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Copper containing intrauterine device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-containing IUD (Mirena速)</intervention_name>
    <description>Levonorgestrel-containing intrauterine device insertion</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Copper-containing IUD (Paraguard速)</intervention_name>
    <description>Copper-containing intrauterine device insertion</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Paraguard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who desire long-term, reversible contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with coagulopathies&#xD;
&#xD;
          -  History of thrombotic events&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active pelvic infection&#xD;
&#xD;
          -  Known hypersensitivity to progestin&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Sensitivity to copper&#xD;
&#xD;
          -  Uterine anatomy that precludes insertion of an IUD&#xD;
&#xD;
          -  Women with multiple sexual partners and history within the last 5 years of alcoholism&#xD;
             or drug abuse.&#xD;
&#xD;
          -  Additionally, women must be greater than 3 months postpartum and have had two months&#xD;
             without oral contraceptive pills or 6 months without Depo Provera prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen P Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia V. Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Penny Fairhurst, RN</last_name>
    <phone>802-847-0985</phone>
    <email>penny.fairhurst@vtmednet.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kristen Wright</name_title>
    <organization>University of Vermont</organization>
  </responsible_party>
  <keyword>Women's health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

